Cancer therapy and cardiovascular risk: Focus on bevacizumab

75Citations
Citations of this article
72Readers
Mendeley users who have this article in their library.

Abstract

Recognition and management of treatment-related cardiovascular toxicity, defined as either an acute cardiac event or a chronic condition, has been tightly integrated into routine cancer care and has become an important component in treatment selection. Several chemotherapeutic agents, such as anthracyclines, are traditionally characterized as cardiotoxic, but cardiovascular adverse events are also associated with commonly used molecular targeted therapies. In the past decade, bevacizumab, a monoclonal humanized antibody against vascular endothelial growth factor, has been introduced in the treatment of a variety of metastatic malignancies. Despite its efficacy, bevacizumab has been associated with significant risk of cardiovascular complications, such as hypertension, cardiac ischemia, and congestive heart failure. This review will focus on the cardiovascular toxicity of bevacizumab, providing the latest evidence on the incidence, clinical spectrum, risk factors, and responsible mechanisms.

Cite

CITATION STYLE

APA

Economopoulou, P., Kotsakis, A., Kapiris, I., & Kentepozidis, N. (2015, June 3). Cancer therapy and cardiovascular risk: Focus on bevacizumab. Cancer Management and Research. Dove Medical Press Ltd. https://doi.org/10.2147/CMAR.S77400

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free